Clinical Trial Update: Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive, HER2-negative invasive breast cancer has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-23